
Lentitek and ViroCell collaborate to address emerging challenges in manufacturing next-generation cell and gene therapies
As cell and gene therapies move toward increasingly complex genetic payloads, manufacturing challenges are emerging as a key bottleneck in the development of the next-generation of therapies. EDINBURGH and LONDON, UK. 23rd March, 2026 – Lentitek Ltd today announced a commercial collaboration that includes the licencing of Lentitek’s proprietary technology







